1. Home
  2. CAPR vs PACB Comparison

CAPR vs PACB Comparison

Compare CAPR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$7.60

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Logo Pacific Biosciences of California Inc.

PACB

Pacific Biosciences of California Inc.

N/A

Current Price

$1.65

Market Cap

696.3M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
PACB
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
584.9M
696.3M
IPO Year
2011
2010

Fundamental Metrics

Financial Performance
Metric
CAPR
PACB
Price
$7.60
$1.65
Analyst Decision
Buy
Buy
Analyst Count
10
8
Target Price
★ $27.25
$2.74
AVG Volume (30 Days)
4.2M
★ 12.7M
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $93,468,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$85.77
$14.03
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3.04
52 Week Low
$2.96
$1.07
52 Week High
$40.37
$3.44

Technical Indicators

Market Signals
Indicator
CAPR
PACB
Relative Strength Index (RSI) 48.38 36.02
Support Level $7.78 $1.61
Resistance Level $10.62 $1.83
Average True Range (ATR) 1.18 0.22
MACD -0.11 -0.09
Stochastic Oscillator 19.61 1.42

Price Performance

Historical Comparison
CAPR
PACB

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Share on Social Networks: